Table 1 Clinical Information of the validation cohort
Characteristic | N = 35 |
|---|---|
Age [M (range), year] | 58 (24–78) |
Gender [n (%)] | Â |
 Male | 26 (74.29) |
 Female | 9 (25.71) |
Location [n (%)] | Â |
 Upper 1/3 | 12 (34.29) |
 Middle 1/3 | 10 (28.57) |
 Lower 1/3 | 10 (28.57) |
 Whole | 1 (2.86) |
 Remnant | 2 (5.71) |
Tumor invasion [n (%)] | Â |
 T2 | 4 (11.43) |
 T3 | 4 (11.43) |
 T4a | 19 (54.28) |
 T4b | 8 (22.86) |
Lymph node [n (%)] | Â |
 N0 | 1 (2.86) |
 N1–3 | 34 (97.14) |
Distant metastasis [n (%)] | Â |
 M0 | 17 (48.57) |
 M1 | 18 (51.43) |
cTNM stage [n (%)] | Â |
 2A | 3 (8.57) |
 2B | 1 (2.86) |
 3 | 9 (25.71) |
 4A | 4 (11.43) |
 4B | 18 (51.43) |
Differentiation [n (%)] | Â |
 Moderate | 5 (14.29) |
 Poor | 30 (85.71) |
Anti-PD-1 agent [n (%)] | Â |
 Camrelizumab | 11 (31.43) |
 Tislelizumab | 1 (2.86) |
 Pembrolizumab | 3 (8.57) |
 Nivolumab | 8 (22.85) |
 Sintilimab | 12 (34.29) |
 Received cycles of anti-PD-1 therapy [M (range)] | 3 (2–11) |
Chemotherapy [n (%)] | Â |
 SOX | 33 (94.28) |
 CapeOx | 1 (2.86) |
 Paclitaxel plus carboplatin | 1 (2.86) |
 Follow-up time [M (range), months] | 6.9 (1.7–18.2) |
 PFS [M (range), months] | 6.3 (1.7–17.0) |
 OS [M (range), months] | 13.7 (1.7–18.2) |